Literature DB >> 16799237

Elevated plasma osteopontin levels were associated with osteopontin expression of CD4+ T cells in patients with unstable angina.

Hirofumi Soejima1, Atsushi Irie, Takashi Fukunaga, Koichi Sugamura, Sunao Kojima, Tomohiro Sakamoto, Michihiro Yoshimura, Hideki Kishikawa, Yasuharu Nishimura, Hisao Ogawa.   

Abstract

BACKGROUND: Plaque instability in patients with unstable angina (UA) is associated with stimulated CD4+ T cells, so the present study investigated whether there is a relationship among plaque instability, osteopontin and CD4+ T cells. METHODS AND
RESULTS: Peripheral blood mononuclear cells were collected from 51 consecutive patients with UA, 60 patients with stable angina (SA), and 39 patients with chest pain syndrome (CPS). Osteopontin-producing CD4+ T cells were quantified by flow cytometry. Plasma osteopontin levels (ng/ml) were measured by ELISA and were higher in patients with UA (792.0 +/- 316.7) than in those with SA (626.0 +/- 195.0, p < 0.005) or CPS (594.7 +/- 239.4, p < 0.005). The frequency (%) of osteopontin-producing CD4+ T cells was higher in patients with UA (26.7 +/- 13.3) than in those with SA (19.5 +/- 11.1, p < 0.05) or CPS (16.6 +/- 9.0, p < 0.005). Furthermore, the plasma osteopontin level correlated with the frequency of osteopontin-producing CD4+ T cells (r = 0.327, p = 0.0004), as did the high-sensitivity C-reactive protein level (r = 0.360, p = 0.0002).
CONCLUSIONS: The plasma osteopontin levels are elevated in patients with UA, accompanied by an increase in the number of osteopontin-production of circulating CD4+ T cells. Circulating CD4+ T cells may play a role through osteopontin in the pathophysiology of UA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16799237     DOI: 10.1253/circj.70.851

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  5 in total

1.  Dephosphorylation of circulating human osteopontin correlates with severe valvular calcification in patients with calcific aortic valve disease.

Authors:  Rachana Sainger; Juan B Grau; Paolo Poggio; Emanuela Branchetti; Joseph E Bavaria; Joseph H Gorman; Robert C Gorman; Giovanni Ferrari
Journal:  Biomarkers       Date:  2011-12-23       Impact factor: 2.658

2.  Associations between plasma osteopontin levels and the severities of coronary and aortic atherosclerosis.

Authors:  Yukihiko Momiyama; Reiko Ohmori; Zahi A Fayad; Teruyoshi Kihara; Nobukiyo Tanaka; Ryuichi Kato; Hiroaki Taniguchi; Masayoshi Nagata; Haruo Nakamura; Fumitaka Ohsuzu
Journal:  Atherosclerosis       Date:  2010-01-04       Impact factor: 5.162

3.  Osteopontin protects against cardiac ischemia-reperfusion injury through late preconditioning.

Authors:  Yongyi Wang; Baofu Chen; Dafu Shen; Song Xue
Journal:  Heart Vessels       Date:  2009-04-01       Impact factor: 2.037

4.  Changes in serum angiogenic factors among patients with acute pain and subacute pain.

Authors:  Xuewei Yang; Chunmei Yuan; Huanling Wang; Yunxia Wang; Mei Liu; Zongjin Li; Jun Zhang
Journal:  Front Mol Neurosci       Date:  2022-07-15       Impact factor: 6.261

Review 5.  Clinical and Molecular Implications of Osteopontin in Heart Failure.

Authors:  Argen Mamazhakypov; Meerim Sartmyrzaeva; Akpay Sh Sarybaev; Ralph Schermuly; Akylbek Sydykov
Journal:  Curr Issues Mol Biol       Date:  2022-08-11       Impact factor: 2.976

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.